Wednesday, March 18, 2020

3D model: how Remdesivir binds to SARS-CoV-2

https://www.youtube.com/watch?v=DKLLKP7pk0o


On March 6, when Gilead Sciences announced clinical trials of their anti-viral medication Remdesivir, I bought shares in their stock (and yes, it is up).  Coincidentally, one of my children had an assignment at University to model how the medication (Remdesivir) binds to SARS-CoV-2.

Here is the video.


No comments: